Kucur Mine, Isman Ferruh K, Balci Can, Onal Bulent, Hacibekiroglu Munire, Ozkan Ferda, Ozkan Alper
Fikret Biyal Central Research Laboratory, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
Urol Oncol. 2008 Jan-Feb;26(1):47-52. doi: 10.1016/j.urolonc.2007.07.020.
YKL-40, also called human cartilage glycoprotein-39 (HC gp-39) and chitotriosidase are homologs of family 18 glycosyl hydrolases secreted by human macrophages. Although high levels of YKL-40 and chitotriosidase are associated with several diseases, the physiological functions of these enzymes are still unclear. YKL-40, a growth factor for connective tissue cells, a migration factor for endothelial and vascular smooth muscle cells, is expressed by several types of solid human carcinoma, including prostate carcinoma.
The purpose of this study was to compare serum YKL-40 levels and chitotriosidase activity both in benign prostatic hyperplasia and primary prostate cancer.
YKL-40 and chitotriosidase were determined in serum samples from 93 patients with primary prostate cancer and 61 patients with benign prostatic hyperplasia. Serum YKL-40 levels were measured by ELISA and chitotriosidase activity was determined by fluorometer. PSA levels were also measured by using an automated system.
Serum YKL-40 levels were significantly higher (P < 0.001) in patients with prostate cancer compared with control group whereas there was no significant difference between BPH and control group. Serum chitotriosidase activities were significantly higher in carcinoma patients with high Gleason score than the control group (P < 0.001). No significant difference was observed in BPH patients (P > 0.05). Both YKL-40 and chitotriosidase were found statistically significant higher in primary prostate cancer and BPH.
High serum YKL-40 levels in patients with primary prostate cancer indicate that YKL-40 may have a function in the progression of malignant diseases, whereas no significant elevation was observed in benign prostatic hyperplasia. Meanwhile, high serum chitotriosidase activity was observed only in patients with Gleason high grade, indicating possible macrophage involvement in cancer progression. Further studies are needed to elucidate the biologic role of YKL-40 in cancer aggressiveness and in progression of malignant diseases.
YKL - 40,也称为人软骨糖蛋白-39(HC gp - 39)和壳三糖苷酶,是人类巨噬细胞分泌的18家族糖基水解酶的同源物。尽管YKL - 40和壳三糖苷酶的高水平与多种疾病相关,但这些酶的生理功能仍不清楚。YKL - 40是一种结缔组织细胞生长因子,一种内皮细胞和血管平滑肌细胞迁移因子,在包括前列腺癌在内的几种人类实体癌中表达。
本研究的目的是比较良性前列腺增生和原发性前列腺癌患者血清YKL - 40水平和壳三糖苷酶活性。
测定93例原发性前列腺癌患者和61例良性前列腺增生患者血清样本中的YKL - 40和壳三糖苷酶。采用酶联免疫吸附测定法(ELISA)检测血清YKL - 40水平,用荧光计测定壳三糖苷酶活性。前列腺特异性抗原(PSA)水平也使用自动化系统进行测定。
前列腺癌患者血清YKL - 40水平显著高于对照组(P < 0.001),而良性前列腺增生组与对照组之间无显著差异。高Gleason评分的癌症患者血清壳三糖苷酶活性显著高于对照组(P < 0.001)。良性前列腺增生患者中未观察到显著差异(P > 0.05)。原发性前列腺癌和良性前列腺增生患者的YKL - 40和壳三糖苷酶在统计学上均显著升高。
原发性前列腺癌患者血清YKL - 40水平升高表明YKL - 40可能在恶性疾病进展中起作用,而良性前列腺增生患者未观察到显著升高。同时,仅在高Gleason分级患者中观察到高血清壳三糖苷酶活性,表明巨噬细胞可能参与癌症进展。需要进一步研究以阐明YKL - 40在癌症侵袭性和恶性疾病进展中的生物学作用。